COVID-19 therapy / Merck (MSD), Institute for Systems Biology - LARVOL DELTA

Oropharyngeal resistome remains stable during COVID-19 therapy, while fecal resistome shifts toward a less diverse resistotype. (PubMed, iScience) - "Our findings suggest that the fecal resistome is a dynamic system that can exist in certain "states" and is capable of transitioning from one state to another. To date, this is the first study to comprehensively describe the oropharyngeal resistome and its variability over time, and one of the first studies to demonstrate the temporal dynamics of the fecal resistotypes."

Journal • Infectious Disease • Novel Coronavirus Disease

Prevalence of Potential Drug-Drug Interactions With Ritonavir-Containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey. (PubMed, Clin Ther) - "Approximately one-third of the US population would be at risk for a major or contraindicated pDDI should they receive a ritonavir-containing regimen, and this risk increases significantly among individuals 60 years or older and with comorbidities such as serious heart conditions, CKD, diabetes, and HIV. The state of polypharmacy in the US population and the quickly changing COVID-19 landscape indicate significant risk of pDDIs among those requiring treatment with ritonavir-containing COVID-19 medications. Practitioners should take polypharmacy, age, and comorbidity profile into account when prescribing COVID-19 therapies. Alternative treatment regimens should be considered, especially for those of older age and those with risk factors for progression to severe COVID-19."

Journal • Chronic Kidney Disease • Diabetes • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Renal Disease • CYP3A4

Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy. (PubMed, J Manag Care Spec Pharm) - "Financial support for this study was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. The study sponsor was involved in the design and conduct of the study; collection, management, analysis, interpretation of data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication."

Journal • Infectious Disease • Novel Coronavirus Disease

"What is the future of COVID-19 therapeutics? The upcoming #WAC panel will include discussions on the key areas of focus for 2023 and beyond... 🔴💉 📌 Commodore A & B ⏱️ 09:10 @gatesfoundation @BARDA @Merck @HHSGov" (@AntiviralWorld)

Infectious Disease • Novel Coronavirus Disease

[VIRTUAL] COVID-19 Therapeutics: Modality, Efficacy and Implications for Access (BIO 2021) - "This has led to a broad array of novel approaches to treating patients infected with the virus—from antibodies that could be given as prevention, to treatments that help reduce the impact of the “cytokine storm,” or Acute Respiratory Distress Syndrome (ARDS). Hear from top scientists and industry leaders about the development of these non-vaccine treatment options and the challenges in achieving global access to them."

Clinical • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases